Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853027 | 0.82 | ALDH1A1 (0.72) | ALDH1A1LMNAKDM4ETDP1MAPT | |
| SCHEMBL27075997 | 0.81 | ALDH1A1 (0.53) | ALDH1A1LMNAKDM4ETDP1MAPT | |
| SCHEMBL30648625 | 0.78 | ALDH1A1 (0.41) | ALDH1A1KDM4ETDP1MAPTMEN1 | |
| SCHEMBL26641021 | 0.78 | ALDH1A1 (0.41) | ALDH1A1KDM4ETDP1MAPTMEN1 | |
| SCHEMBL16825132 | 0.78 | ALDH1A1 (0.71) | ALDH1A1LMNAKDM4ETDP1MAPT | |
| SCHEMBL27993656 | 0.78 | TDP1 (0.54) | ALDH1A1LMNAKDM4ETDP1MAPT | |
| SCHEMBL4879328 | 0.78 | ALDH1A1 (0.51) | ALDH1A1LMNAKDM4ETDP1MAPT | |
| SCHEMBL25404203 | 0.77 | ALDH1A1 (0.60) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL29507768 | 0.77 | ALDH1A1 (0.66) | ALDH1A1LMNAKDM4ETDP1MAPT | |
| SCHEMBL855387 | 0.77 | HTT (0.55) | ALDH1A1LMNAKDM4ETDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2023220541-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | ALDH1A1 3576/4885LMNA 4540/4885KDM4E 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.